Chikako Shimizu

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy et al. · The Lancet Oncology · 2022 · 566 citations · Full text

Medicine, Endocrinology, Oncology +14

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito et al. · The Lancet Oncology · 2017 · 501 citations

Medicine, Oncology, Pharmacology +17

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín et al. · Annals of Oncology · 2021 · 378 citations · Full text

Medicine, Oncology, Pharmacology +16

Novel combination of serum microRNA for detecting breast cancer in the early stage

Akihiko Shimomura, Sho Shiino, Junpei Kawauchi et al. · Cancer Science · 2016 · 363 citations · Full text

Medicine, Cancer Biology, Oncology +15

⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Kenji Tamura, Hiroaki Kurihara, Kan Yonemori et al. · Journal of Nuclear Medicine · 2013 · 295 citations · Full text

Medicine, Nuclear Medicine, Oncology +17